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Abstract
While exposure to hexavalent chromium (Cr(VI)) has been associated with increased lung cancer
risk for more than 50 years, the chemical is not currently regulated by the U.S. Occupational Safety
and Health Administration (OSHA) on the basis of its carcinogenicity. The agency was petitioned
in 1993 and sued in 1997 and 2002 to lower the workplace Cr(VI) exposure limit, resulting in a
court order to issue a final standard by February 2006. Faced with the threat of stronger regulation,
the chromium industry initiated an effort to challenge the scientific evidence supporting a more
protective standard. This effort included the use of "product defense" consultants to conduct post
hoc analyses of a publicly-funded study to challenge results viewed unfavorably by the industry.
The industry also commissioned a study of the mortality experience of workers at four low-
exposure chromium plants, but did not make the results available to OSHA in a timely manner,
despite multiple agency requests for precisely these sorts of data. The commissioned study found
a statistically significant elevation in lung cancer risk among Cr(VI)-exposed workers at levels far
below the current standard. This finding changed when the multi-plant cohort was divided into two
statistically underpowered components and then published separately. The findings of the first
paper published have been used by the chromium industry to attempt to slow OSHA's standard
setting process. The second paper was withheld from OSHA until it was accepted for publication
in a scientific journal, after the rulemaking record had closed.
Studies funded by private sponsors that seek to influence public regulatory proceedings should be
subject to the same access and reporting provisions as those applied to publicly funded science.
Parties in regulatory proceedings should be required to disclose whether the studies were
performed by researchers who had the right to present their findings without the sponsor's
consent or influence, and to certify that all relevant data have been submitted to the public record,
whether published or not.
Background
In recent years, efforts by major corporations to deflect
unwanted scientific findings have been reported increas-
ingly in the lay and biomedical literature. The tobacco
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industry, for example, used the attorney-client privilege to
shelter scientific studies from disclosure [1-3]; it also
funded apparently independent organizations to provide
a patina of credibility for its work [1,4]. Pharmaceutical
manufacturers have withheld unfavorable clinical trial
results [5,6] and have disparaged research that produced
unwelcome findings [7,8].
We report a case in the less-scrutinized field of occupa-
tional health in which all these elements were combined
in a coordinated strategy to challenge the Occupational
Safety and Health Administration's (OSHA) action to
reduce workers' exposures to the lung carcinogen hexava-
lent chromium (Cr(VI)).
Cr(VI) is not a newly-identified hazard; the increased risk
of lung cancer has been documented in Cr(VI)-exposed
workers for more than 50 years [9,10]. Thomas F. Man-
cuso and Wilhelm C. Hueper, for example, studied the
mortality experience of chromium-exposed workers
employed between 1931 and 1937 at a Painesville, Ohio
facility. Results of their study were published in 1951
[10,11], with updates on the cohorts published by Dr.
Mancuso in 1975 [12] and again in 1997 [13], consist-
ently finding an excess risk of lung cancer among exposed
workers. Cr(VI) has been classified as a human carcinogen
by the National Toxicology Program [14] and the Interna-
tional Agency for Research on Cancer [15].  It is used in
chrome plating and in the production of metal alloys and
pigments. OSHA estimates that approximately 380,000
U.S. workers are currently exposed to Cr(VI) [16].
At present, OSHA does not regulate Cr(VI) on the basis of
its carcinogenicity. The agency's current Permissible Expo-
sure Limit (PEL) of 52 ug/m3 was originally recommended
in 1943 by the American National Standards Institute as a
level adequate to prevent nasal perforations in chromium-
exposed workers [17]. This 52 ug/m3 limit was adopted by
OSHA in 1971 when the agency was created, without any
formal review. In 1976, OSHA announced plans to lower
the Cr(VI) standard [18] and in 1994, the OSHA adminis-
trator acknowledged that "there is clear evidence that
exposure...at the current PEL...can result in an excess risk
of lung cancer" [19]. However, until recently, no change
was officially proposed and the 52 ug/m3 PEL remains in
effect today.
In 1993, Public Citizen and the Oil, Chemical and Atomic
Workers International Union (OCAW) (now part of the
United Steelworkers) petitioned OSHA to reduce its PEL
from the current level of 52 ug/m3 to 0.25 ug/m3, meas-
ured as an 8-hour time-weighted average. Two lawsuits
ensued, challenging OSHA's "unreasonable delay" in
promulgating a stronger standard. Although the chro-
mium industry, through its trade association the Chrome
Coalition, had intervened in the lawsuits on OSHA's
behalf opposing a change in the PEL, on April 2, 2003, the
U.S. Court of Appeals for the Third Circuit ordered the
agency to issue a final rule reducing occupational expo-
sure to Cr(VI) by January 18, 2006 [20], later extended to
February 28, 2006. In the words of Judge Edward Becker,
OSHA's decade-long delay in issuing a Cr(VI) standard
"exceeded the bounds of reasonableness" [21].
The industry strategy to forestall OSHA rulemaking
Long before the court ruling, however, the chromium
industry had initiated an effort to challenge the scientific
evidence supporting any stronger OSHA standard, engag-
ing the services of ChemRisk and Exponent, Inc., two con-
sulting firms that specialize in "litigation support" and
"product defense" [22,23]. One industry document noted
that "this route [hiring the consultants] is expensive and
success is not guaranteed, [but] the longer we wait the
more difficult the task becomes." [See additional file 1:
File1 to view this document.]
In a meeting with chromium industry representatives in
1996, ChemRisk scientists outlined a strategy that
included obtaining and analyzing the raw data from a
not-yet-published study of Cr(VI) exposure funded by the
Environmental Protection Agency (EPA) in order "to fore-
stall the [OSHA] rulemaking." [See additional file 2: File2
to view this document.] Simultaneously, the industry
commissioned new publications that questioned the
health effects of low levels of exposure to Cr(VI) [24-26],
a central issue in any OSHA regulatory initiative. The
industry paid for services provided by ChemRisk and
Exponent, Inc. through its trade association's attorneys.
This arrangement was selected to "...preserve the confi-
dentiality of information, opinion, and data to the extent
provided for under the attorney-client privilege and attor-
ney work product privilege." [See additional file 3: File3 to
view this document], ensuring that material developed
through the process could be sequestered from public
view. [See additional file 4: File4 to view meeting sum-
mary and plan to preserve attorney-client privilege.]
The industry also contracted with a third consulting firm,
ENVIRON [27], to study workers who had only been
employed in facilities that were either designed with or
converted to production processes that resulted in lower
levels of Cr(VI) exposure. ENVIRON was hired through a
contract with the Industrial Health Foundation (IHF), a
descendant of the Air Hygiene Foundation, an organiza-
tion founded in 1935 in the wake of the 1930's Gauley
Bridge occupational silicosis tragedy to provide employers
with confidential assessments of industrial hazards [28].
The study protocol entailed combining workers from four
plants using newer, lower-exposure processes – two in the
U.S. (Castle Hayne, NC, and Corpus Christi, TX) and twoEnvironmental Health: A Global Access Science Source 2006, 5:5 http://www.ehjournal.net/content/5/1/5
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in Germany – into a single cohort. ENVIRON's proposal
noted that "the relatively small study sizes and short fol-
low-up periods resulted in a limited ability of [previous]
studies to clarify the relationship between modern [low-
level] occupational chromate exposures and cancer in
general, and respiratory cancers in particular." According
to the proposal, creating a single cohort with workers
from multiple plants was crucial "to improve statistical
power and the inferential value of the results" [29].
In August 2000, the EPA study was published. It is the
largest, most comprehensive study ever conducted on the
effects of workplace Cr(VI) exposure. The study examined
a cohort of more than 2,300 workers employed at a chro-
mate production facility in Baltimore, MD, from 1950 to
1974, and followed through 1992. Exposure histories
were reconstructed utilizing 70,000 measures of airborne
Cr(VI) concentrations; smoking histories for 93% of the
cohort were also incorporated into the analyses. Using
OSHA's standard assumption of a 45-year working life-
time, the study reported a significantly elevated lung can-
cer risk of 1.57 among workers whose mean exposure was
at levels just above the PEL requested in the Public Citi-
zen-OCAW petition [30].
No sooner had the EPA study been published than the
industry-sponsored critiques began. Scientists with the
product defense firm Exponent, Inc. created and analyzed
the mortality experience of a "simulated cohort" derived
by computer from the EPA study's summary data, stand-
ard deviations and ranges [31]. In another report, the con-
sultants obtained the raw data from the EPA study
through a Freedom of Information Act request and re-ana-
lyzed them [32]. Each of these reports challenged the
validity of the EPA study's conclusions and was either
entered into the record in litigation or submitted to OSHA
by the chromium industry, although not published in the
peer-reviewed literature. After extensive analysis, most of
the issues raised in these critiques were rejected by OSHA
[33].
OSHA publishes its proposed rule
On October 4, 2004, OSHA published its court-mandated
proposed rule for Cr(VI), including a PEL of 1 ug/m3 [34].
The agency issued a general request for additional scien-
tific evidence, along with a specific appeal for epidemio-
logical data about the aforementioned cohort in Castle
Hayne, where exposure levels were more representative of
the concentrations of airborne Cr(VI) found in work-
places today [35]. A mortality study of this group had
been published in 1994 [36] and OSHA asked directly,
"Are there updated analyses available for [this cohort]?"
In addition, OSHA asked, "Are there other cohorts availa-
ble to look at low exposures?" [37].
Following a three-month comment period, OSHA held 11
days of public hearings [38], at which OSHA reiterated its
request for more data and industry repeatedly criticized
OSHA for relying on data from high-exposure cohorts
[39-44]. In reviewing the hearing transcript, we found no
mention by industry representatives or anyone else of any
imminent new epidemiological evidence. The public was
given until April 20, 2005, to submit additional data and
post-hearing comments.
Selected science
Just weeks before the close of the comment period, a study
reporting on the mortality experience of workers
employed at the Castle Hayne and Corpus Christi facili-
ties appeared in the Journal of Occupational and Environ-
mental Medicine (JOEM) [45]. The article had been
submitted to JOEM in July 2004 and was accepted for
publication that October [46], the same month OSHA
proposed its rule and specifically asked for information
about the Castle Hayne or other cohorts. The analysis has
little statistical power (only three lung cancer deaths) and
suffers from short follow-up (fewer than half of the work-
ers in the study were followed for twenty years or more,
the minimum length of time needed to begin to detect
occupational cancer) [47]. Even though they collected
data on Cr(VI) exposure, none is presented in the paper
and the small sample size precludes logistic regression.
Nonetheless, the authors offer the "preliminary conclu-
sion" that "the absence of an elevated lung cancer risk at
this time may be a favorable reflection of the post-change
[i.e., lower exposure] environment [45]."
Three trade associations made reference to the study in
their post-hearing comments [48-50]. For example, the
Specialty Steel Industry of North America stated it had
"recently" learned of the study:
[W]hile we have not had any opportunity to examine this
study...[it] contains potentially incredibly significant data
which would allow the development of a dose response
relationship based on actual, experienced exposures, as
opposed to the modeled exposures upon which OSHA
currently relies to set the PEL. Indisputably, this would be
much more relevant and appropriate data upon which to
establish a risk-based regulatory limit [48].
The Specialty Steel Industry warned that OSHA's failure to
consider these results would be "arbitrary and capricious,"
a legal term, signaling that failure to address these "new"
findings would be grounds for a legal challenge. The Soci-
ety of the Plastics Industry, Inc. (SPI) remarked on the
"potentially great significance" [49] of the new ENVIRON
study.Environmental Health: A Global Access Science Source 2006, 5:5 http://www.ehjournal.net/content/5/1/5
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Moreover, the comments by these trade associations con-
firm that they were privy to unpublished details of the
ENVIRON analysis. For example, one wrote:
SPI has learned that in the German plants, excess lung
cancer mortality was demonstrated only in the highest
exposure group, using chromium exposure estimates
based on urinary chromium results. It is possible that the
data obtained from the German facilities demonstrates
that no increase in risk at any but the highest exposure lev-
els to CrVI [49].
The industry thus succeeded in inserting this hearsay
material into the record without ever providing the actual
study data.
Intrigued by these developments, we conducted an Inter-
net search, using the terms "Industrial Health Founda-
tion" and "Chrome Coalition." To our surprise, we
located a notice for a hearing related to the bankruptcy of
IHF. In this proceeding, two chromium industry trade
associations asserted that files in the possession of IHF
actually belonged to the industry, because the IHF was,
according to the petitioner, simply a "third-party admin-
istrator of the trade association." [See additional file 5:
File5 to view this document.] Using the Public Access to
Court Electronic Records system [51], we obtained docu-
ments filed with the court, some of which have been
quoted in this manuscript. These materials also led us to
parties in the bankruptcy proceedings who provided addi-
tional documents, including ENVIRON's study protocol
and the final report of the combined study of the U.S. and
German plants.
That report, submitted by ENVIRON to IHF in September
2002 but never by the industry to OSHA and never pub-
lished in its entirety, provides strong support for the inad-
equacy of the current standard, and raises questions about
whether the proposed OSHA PEL of 1 ug/m3 is adequately
protective. The ENVIRON authors found a significantly
elevated risk of lung cancer mortality associated with
exposure to Cr(VI) in these newer low-exposure facilities
(SMR = 1.66, 95% CI = 1.08–2.46, using a combination of
German national rates and U.S. state rates for comparison;
SMR = 1.37, 95% CI = 0.89–2.03, using German and U.S.
state rates). The investigators developed a series of job
exposure matrices and utilized air monitoring data from
the U.S. plants and urine monitoring from the German
plants to estimate the exposure history of each worker. In
order to convert the urinary measurements (ug/L) into air
measurements (ug/m3), we divided by 0.77, the same con-
version factor used by the industry [52], and divided by
45, to convert cumulative exposures into mean annual
ones.
Logistic regression analyses of the four-plant cohort found
increased risk associated with increased cumulative (or
lifetime) exposure to Cr(VI). In one analysis, the lung can-
cer mortality odds ratio among workers with highest
annual exposure (≥ 5.8 ug/m3) was 20.2 (95% CI = 6.2–
65.4), compared to the lowest exposure group (< 1.2 ug/
m3) [53]. For the intermediate exposure group (1.2 ug/m3
– < 5.8 ug/m3), the odds ratio was 4.9 (95% CI = 1.5–
16.0), also in comparison to the lowest exposure group
[53]. Thus, the intermediate group includes exposure at
levels only slightly higher than the 1 ug/m3 PEL proposed
by OSHA in 2004, and showed elevated lung cancer risk
at that level.
The final unpublished four-plant report reiterated the
strength of the study design: "This study benefited from
the multi-site design that provided a reasonably large
cohort of post-change [lower exposure] chromium chem-
ical workers, along with the corresponding increase in sta-
tistical power generally lacking in previous studies of post-
change cohorts" [52].
The published JOEM article, however, reports the mortal-
ity experience only of workers at the two U.S. plants stud-
ied by the ENVIRON researchers. After submitting the
results to their sponsors in 2002, the authors evidently
separated the German and U.S. results, despite their
repeated emphasis in the protocol on the strength of the
combined cohort. Instead of a positive result based on
four plants, a negative two-plant study was published. In
a response to a letter [54] in the JOEM, the authors stated
that the German component of the study had not been
published because it was rejected by a journal to which it
had been submitted, and defended the exclusion of the
German data on the ground that different exposure meas-
urements (air vs. urine) were used [55]. This claim is not
consistent with the need for large sample size to increase
statistical power, as stated in the protocol and the final
report. In June 2005, we provided the study protocol [29]
and final report of the four-plant study [52] to OSHA [56].
On October 17, 2005, the ENVIRON researchers submit-
ted the German component of the study to OSHA, accom-
panied by a note saying the paper had been accepted for
publication in JOEM  [57,58]. In this manuscript, the
ENVIRON researchers report that "lung cancer risk was
elevated only in the highest exposure group (SMR = 2.09
95% CI = 1.08–3.65)" [58].
The authors conducted another logistic regression analy-
sis, but in this new version the estimate of relative risk for
workers with high exposure is derived by comparing them
to workers in the low and intermediate exposure groups
combined. The result of this change is the disappearance
of the statistically significant increase in lung cancer mor-Environmental Health: A Global Access Science Source 2006, 5:5 http://www.ehjournal.net/content/5/1/5
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tality risk among the intermediate group that was found
in the unpublished final report. Tables 1 and 2, adapted
from the unpublished final report [52] and the pre-publi-
cation manuscript of the German component of the study
submitted by the authors to OSHA [58], respectively,
compare the results of the two regression analyses. In
addition, while the elevation of the lung cancer SMR in
the unpublished final report of the four-plant study was
statistically significant, when the cohort was divided into
two components, the lung cancer SMR was not statisti-
cally significant in either the German or U.S. components.
Discussion
Faced with the threat of stronger OSHA regulation of
workplace exposure of Cr(VI), a powerful carcinogen, the
chromium industry initiated an effort to challenge the sci-
entific evidence that the agency would likely use to justify
a new standard. While criticizing OSHA for relying upon
data from high-exposure cohorts, the chromium industry
also commissioned a study of the mortality experience of
workers at four plants with lower exposures, the results of
which confirmed the elevated lung cancer risk in such
workers. The consultants presented a final report to their
chromium industry sponsors in 2002, but industry never
provided OSHA a copy of the full four-plant study. Even
when the agency specifically asked for precisely these sorts
of data during its 2004–2005 rulemaking proceedings, the
chromium industry and the authors remained silent.
For publication, industry-funded scientists divided this
study into two components and published them sepa-
rately. The first paper to be published was a statistically
underpowered, negative study, the findings of which are
being used by industry to attempt to reduce its regulatory
burden. The second paper combined two exposure strata
from the final report, resulting in the disappearance of the
stratum of particular regulatory interest in which a statis-
tically significant finding was apparent in the unpub-
lished final report. This allowed the industry trade
associations to make the misleading assertion that ele-
vated lung cancer mortality risk was only seen among
workers with the highest exposure histories.
OSHA's statute instructs its decision makers to use the
"best available evidence" [59] in the rulemaking process.
The circumstances regarding these studies raise troubling
questions about the ability of government to effectively
issue rules protecting public health when studies are con-
ducted, controlled and selectively published or provided
to the rulemaking agency by the regulated industry [8,60].
The entry of the German study into the OSHA record only
after it was accepted for publication, months after the reg-
ulatory docket closed and years after data collection was
complete, raises an important question for public health
research: when regulatory proceedings are underway,
should potentially important data be sequestered until
the peer review process is complete? Many U.S. regulatory
agencies, including the EPA and the Food and Drug
Administration (FDA) rely heavily on unpublished stud-
ies, submitted by study sponsors, in reaching regulatory
decisions. In this case, sponsors withheld data that OSHA
requested during an active rulemaking process.
Table 1: Elevated lung cancer mortality risk in intermediate and high exposure groups in original unpublished study†
Mean Exposure to Cr(VI)* OR** 95% CI
Low (< 1.2 ug/m3)R e f - -
Intermediate (1.2 – <5.8 ug/m3) 4.9 1.5 – 16.0
High (≥ 5.8 ug/m3) 20.2 6.2 – 65.4
†Adapted from Table 17 in: Final report: Collaborative cohort mortality study of four chromate production facilities, 1958–1998 [53].
*Mean Exposure to Cr(VI) derived by dividing cumulative urinary chromium exposure by 0.77 (conversion factor for air concentration), and then 
dividing by 45 years (OSHA's working life assumption); see text for details.
**Odds Ratio
Table 2: Lung cancer mortality risk in intermediate group disappears after German component of study published separately††
Mean Exposure to Cr(VI)* OR** 95% CI
Low and Intermediate (<5.8 ug/m3)R e f - -
High (≥ 5.8 ug/m3) 6.9 2.6 – 18.2
††Adapted from Birk T, Mundt KA, Dell LD, et al: Lung cancer mortality in the German chromate industry, 1958–1998. J Occup Environ Med (in 
press) [58].
*Mean Exposure to Cr(VI) derived by dividing cumulative urinary chromium exposure by 0.77 (conversion factor for air concentration), and then 
dividing by 45 years (OSHA's working life assumption); see text for details.
**Odds RatioEnvironmental Health: A Global Access Science Source 2006, 5:5 http://www.ehjournal.net/content/5/1/5
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It is now widely recognized that pharmaceutical manufac-
turers have an obligation to report the existence and
results of all clinical trials, although this is often not done
satisfactorily [61,62]. The higher standards of practice
now being sought in the reporting of pharmaceutical trial
results should also be applied in occupational health and
safety research. The editors of thirteen leading journals
will no longer publish articles based on studies done
under contracts in which clinical trial investigators did not
have the unfettered right to publish the findings, asserting
that such restrictions "erode the fabric of intellectual
inquiry that has fostered so much high-quality clinical
research" [63]. Parties in regulatory proceedings should be
required to disclose whether the studies they submit were
performed by researchers who had the right to present or
publish their findings without the sponsor's consent or
influence [64]. Regulatory agencies should weigh the sub-
mitted information accordingly.
Public health is not well served by the unequal treatment
of public and private science [65]. Parties submitting sci-
entific analyses and reports to the record should be
required to disclose the true sponsorship of the study,
including the original source of the sponsor's funding.
Parties involved in the rulemaking process should also be
required to certify that they have submitted all relevant
data to the public record, whether or not those data have
undergone peer review. Medical journals are increasingly
willing to publish findings even if they have already been
made available in another form. Regardless, public health
rulemakings should not be based on partial records or
limited by scientists' career concerns, particularly when
lives hang in the balance.
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